KRAS and non-small cell lung carcinoma: Similarly, in a study of 102 NSCLC patients with EGFR mutation (22%), KRAS mutation (27%) and wild-type profiles (51%), it was observed that 18F-FDG uptake was significantly higher in those harbouring KRAS mutations as compared to EGFR+ or wild-type (SUVmean 9.5 vs. 5.7 vs. 6.6, p < 0.001) [17].